Cancer and Metastasis Reviews

Papers
(The TQCC of Cancer and Metastasis Reviews is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities358
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer226
Obesity and cancer221
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms142
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions140
The functions and modifications of tRNA-derived small RNAs in cancer biology118
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression107
Clonal tracking in cancer and metastasis91
Regulation of dormancy during tumor dissemination: the role of the ECM84
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?71
Targeting lipid metabolism in cancer: neuroblastoma69
CAR T-cell therapy to treat multiple myeloma: current state and future directions68
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer61
p73 isoforms meet evolution of metastasis60
Cell-cell interactions mediating primary and metastatic breast cancer dormancy59
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review56
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?47
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives47
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond46
Biography—Mathieu Boissan, Pharm.D., Ph.D45
Preface42
Neuropeptide Y in cancer—biological functions and potential clinical implications40
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer40
Biographies39
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance39
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance37
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy36
The role of cancer cell bioenergetics in dormancy and drug resistance36
Short-chain fatty acids in cancer pathogenesis36
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications36
Clusterin: a marker and mediator of chemoresistance in colorectal cancer35
Tumor necrosis factor superfamily signaling: life and death in cancer35
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy35
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development35
Clinical interventions to break the obesity and cancer link: a narrative review34
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions34
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy33
The emerging roles of histone demethylases in cancers33
Vaping and tumor metastasis: current insights and progress33
Carcinoma of unknown primary (CUP): an update for histopathologists32
Functional and clinical roles of stromal PDGF receptors in tumor biology31
Kenneth V. Honn, Ph.D. (1946–2023)30
OX40/OX40 ligand and its role in precision immune oncology29
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape29
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution29
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy28
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective27
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect27
New progress of tuberculosis scar carcinoma26
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases26
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting26
HOXA9 transcription factor is a double-edged sword: from development to cancer progression25
Ferroptosis: iron release mechanisms in the bioenergetic process25
Biographies24
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics24
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases24
Is cancer an intelligent species?24
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies24
2.4760520458221